Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK2 | O96017 | 1/20 | 0.45 |
| ▸ | PRMT5 | O14744 | 5/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | DHODH | Q02127 | 4/20 | 0.41 |
| ▸ | SCD | O00767 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL711040 | 0.95 | DHODH (0.45) | CHEK2PRMT5MEN1KMT2ADHODH | |
| Trifluoroacetic Acid SCHEMBL712661 | 0.94 | CHEK2 (0.41) | CHEK2PRMT5MEN1KMT2ADHODH | |
| Trifluoroacetic Acid SCHEMBL713011 | 0.93 | GCK (0.44) | CHEK2PRMT5DHODHSCD | |
| Trifluoroacetic Acid SCHEMBL711105 | 0.93 | CYP1A1 (0.41) | CHEK2PRMT5DHODHSCD | |
| Trifluoroacetic Acid SCHEMBL711953 | 0.92 | CHEK2 (0.40) | CHEK2PRMT5DHODHSCD | |
| Trifluoroacetic Acid SCHEMBL709196 | 0.91 | FFAR1 (0.42) | CHEK2PRMT5MEN1KMT2ADHODH | |
| Trifluoroacetic Acid SCHEMBL710853 | 0.91 | PPARG (0.39) | CHEK2PRMT5DHODHSCDCYP3A4 | |
| SCHEMBL10206641 | 0.90 | PRMT5 (0.51) | CHEK2PRMT5MEN1KMT2ADHODH | |
| Trifluoroacetic Acid SCHEMBL711483 | 0.87 | GRM5 (0.43) | MEN1KMT2ASCD | |
| Trifluoroacetic Acid SCHEMBL709188 | 0.87 | GCK (0.39) | CHEK2DHODH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1940837-B1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL (JP) | 2012-11-07 | — | — | EP | disclosed |
| US-8124617-B2 | Imidazopyridine compounds | TAKEDA SAN DIEGO, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA SAN DIEGO, INC. | 2010-03-18 | — | — | US | disclosed |
| EP-1940837-A2 | IMIDAZOPYRIDINE COMPOUNDS | Takeda Pharmaceutical Company Limited (JP) | 2008-07-09 | — | — | EP | disclosed |
| WO-2007028135-A2 | IMIDAZOPYRIDINE COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069431-A1 | IMIDAZOPYRIDINE COMPOUNDS | GCK, GCKR, KHK | CHEK2 1189/4885PRMT5 2373/4885MEN1 2868/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.